Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

China’s NMPA Grants Priority Review and Breakthrough Therapy Designation to HUTCHMED’s Sovleplenib for wAIHA Treatment

Summary by GeneOnline News
HUTCHMED has announced that China’s National Medi […]

2 Articles

The Norfolk Daily NewsThe Norfolk Daily News
Center

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited

Read Full Article
GeneOnline NewsGeneOnline News

China’s NMPA Grants Priority Review and Breakthrough Therapy Designation to HUTCHMED’s Sovleplenib for wAIHA Treatment

HUTCHMED has announced that China’s National Medi […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Norfolk Daily News broke the news on Wednesday, April 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

China icon

China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal